JPRN-UMIN000016494
Recruiting
未知
A Pilot Study of Dasatinib for Relapsed or Refractory ABL1/PDGFRB Rearrangemennt Positive Ph-like Acute Lymphoblasic Leukemia - D-APPLE STUDY
ational Center for Child Health and Development0 sites3 target enrollmentFebruary 10, 2015
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- ABL1/PDGFRB Rearrangemennt Positive Ph-like Acute Lymphoblasic Leukemia
- Sponsor
- ational Center for Child Health and Development
- Enrollment
- 3
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients with severe CNS or gastrointestinal hemorrhage (grade 2 or higher in CTCAE ver4\.0\) 2\) Patients with severe fluid retention (grade 2 or higher in CTCAE ver4\.0\) 3\) QTc is more than 0\.45 seconds 4\) Patients with uncontrollable infection (including those with active tuberculosis or positive HIV antibody) 5\) Patient with a history of organ transplantation other than stem cell transplantation 6\) Patient with uncontrollable diabetes mellitus 7\) Patients with history of primary or acquired immunodeficiency 8\) Patients who are pregnant 9\) Patient with 21\-trisomy 10\) Patient with severe mental retardation 11\) Patients with any other inappropriate status judged by physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Dasatinib plus Chemotherapy in Philadelphia Chromosome-Positive Acute Lymphoblastic LeukaemiaACTRN12607000609459Australasian Leukaemia and Lymphoma Group (ALLG)20
Active, not recruiting
Not Applicable
A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to ImatinibSubjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) who are Resistant or Intolerant to Imatinib.EUCTR2006-001279-39-BEBristol-Myers Squibb International Corporation300
Active, not recruiting
Not Applicable
A Phase II Study of Dasatinib (BMS-354825) in Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia who are Resistant or Intolerant to ImatinibSubjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) who are Resistant or Intolerant to Imatinib.EUCTR2006-001279-39-CZBristol-Myers Squibb International Corporation300
Completed
Phase 1
Dasatinib in Relapsed or Refractory Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaNCT00550615University of Nebraska38
Active, not recruiting
Not Applicable
Phase II efficacy and safety study of Dasatinib in Patients with Chronic and Accelerated Phase Chronic Myeloid Leukaemia Relapsing after Allogeneic Blood or Bone Marrow Transplantation - CML DASATINIBchronic myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2008-001361-29-GBEBMT (European group for Blood and Marrow Transplantation)50